Third-generation oral contraceptives and venous thrombosis

[Third generation oral contraceptives and risk of venous thrombosis].

OBJECTIVE To evaluate quantitatively articles that compared effects of second and third generation oral contraceptives on risk of venous thrombosis. DESIGN Meta-analysis. STUDIES Cohort and case-control studies assessing risk of venous thromboembolism among women using oral contraceptives before October 1995. MAIN OUTCOME MEASURES Pooled adjusted odds ratios calculated by a general varian...

Third generation oral contraceptives and vascular risks.

Third generation oral contraceptives (OC), containing the progestins desogestrel and gestodene, were introduced in the 1980s in a attempt to lower the risk of cardiovascular side effects. However, the observation that desogestrel and gestodene in combined OC were related to a 50 to 100% greater risk of venous thromboembolism (VTE) suggested that the issue is more complex than originally thought...

Petition to the FDA to Ban Third Generation Oral Contraceptives Containing Desogestrel due to Increased Risk of Venous Thrombosis

Public Cit izen , represent i ng more than 100 ,000 con sumers nationwide , hereby pet itions the Food and Dr ug Adm i nistra tion (FDA) pursuant to the Federal Food , Drug and Cosmetic Act 2 1 U . S .C . Section 355(e)(3), and 21 C.F .R . 10 .30 , to immed iately ban the th ird generation oral contracept ives contain i~cn .dQmaParrPl d~~tothe approximately doubled risk of venous thrombosi s ( ...

Oral contraceptives and the risk of venous thrombosis.

Cerebral Venous Thrombosis in Patients Using Oral Contraceptives

Cerebral venous thrombosis is a relatively rare, however life-threatening condition. Current studies show that around 10% of the patients die. Earlier works proved that most of the thromboses originated secondarily, as a consequence of local or systemic infection, more than 30% of the cases were considered to be idiopathic. More recent studies also mention other risk factors, which may contribu...